title: Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection.
abstract: OBJECTIVE
  We have evaluated the efficacy of long-term lamivudine monotherapy in patients with decompensated HBeAg-negative/HBV-DNA positive cirrhosis.
  
  
  METHODS
  We analyzed the clinical course and outcome of lamivudine treatment in 30 consecutive cirrhotics and compared with 30 HBV untreated historical HBeAg-negative controls matched for age and gender.
  
  
  RESULTS
  Significant clinical improvement, defined as a reduction of at least two points in Child-Pugh score was observed in 23 of the 30 treated patients (76.6%) versus none of the 30 patients in the control group (p < 0.0001) after a mean follow-up of 20.6 +/- 12.1(+/-SD) months. There were 10 deaths in the treated group versus 24 in the control group (p= 0.07). Liver-related deaths occurred in five of the eight patients soon after the development of biochemical breakthrough. Patients with clinical improvement had better survival than patients with no improvement (p= 0.04) or those who developed biochemical breakthrough due to YMDD mutants (p= 0.001).
  
  
  CONCLUSIONS
  Lamivudine significantly improves liver function in HBeAg-negative decompensated cirrhosis. However, the development of the biochemical breakthrough due to YMDD mutants is associated with fatal outcome.
authors.affiliation: 2nd Department of Gastroenterology, Evangelismos General Hospital, Athens, Greece.
authors.forename: Spilios
authors.initials: S
authors.lastname: Manolakopoulos
authors.forename: Stylianos
authors.initials: S
authors.lastname: Karatapanis
authors.forename: Jiannis
authors.initials: J
authors.lastname: Elefsiniotis
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Mathou
authors.forename: Jiannis
authors.initials: J
authors.lastname: Vlachogiannakos
authors.forename: Elissabet
authors.initials: E
authors.lastname: Iliadou
authors.forename: Anastasios
authors.initials: A
authors.lastname: Kougioumtzan
authors.forename: Michalis
authors.initials: M
authors.lastname: Economou
authors.forename: Christos
authors.initials: C
authors.lastname: Triantos
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Tzourmakliotis
authors.forename: Alec
authors.initials: A
authors.lastname: Avgerinos
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006513:Hepatitis B e Antigens / Q000032:analysis*; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008099:Liver / Q000503:physiopathology; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology / Q000821:virology; D008297:Male; D008875:Middle Aged; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D006513:Hepatitis B e Antigens; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine